July 25, 2016Cardiovascular DiabetologyOpen Access

Effects of the glucagon-like peptide-1 receptor agonist liraglutide on systolic function in patients with coronary artery disease and type 2 diabetes: a randomized double-blind placebo-controlled crossover study

View Full Paper

Ask AI

Bookmark

Why the study?

Does liraglutide improve left ventricular ejection fraction in patients with type 2 diabetes and stable coronary artery disease?

Population

41 subjects with stable coronary artery disease and newly diagnosed type 2 diabetes within 24 months, mean…

Comparison

Liraglutide subcutaneous injections + metformin… vs Matching placebo subcutaneous injections +…

Design

RCT, randomized, double-blind, placebo-controlled

Follow-up

12 weeks per period

Authors

PKPreman KumarathuraiUniversity of Southern Denmark CAChristian AnholmAmager Hospital ONOlav Wendelboe NielsenHeart Failure & Transplant

Discussion

Member takes

Implication

Liraglutide does not improve LVEF in T2D with stable CAD; challenges hypothesized systolic benefits and supports neutral effect in this population.

Structured PICO

Does liraglutide improve left ventricular ejection fraction in patients with type 2 diabetes and stable coronary artery disease?

Population

41 subjects with stable coronary artery disease (LVEF >40%) and newly diagnosed type 2 diabetes within 24 months, mean age 61.8, 79% male, from Denmark.

Intervention

Liraglutide subcutaneous injections (titrated up to 1.8 mg once daily) + metformin tablets for 12 weeks

Comparator

Matching placebo subcutaneous injections + metformin tablets for 12 weeks

Outcome

Change in left ventricular ejection fraction (LVEF) assessed by Simpson's biplane method at rest and during dobutamine stress echocardiographysurrogate

Liraglutide did not improve left ventricular systolic function during dobutamine stress echocardiography or exercise capacity in patients with type 2 diabetes and stable coronary artery disease.

Limitations

Differences in scanning positions may have contributed to overall variation

Cite This Study

Kumarathurai et al. (2016) studied this question.

synapsesocial.com/papers/6a7e445a7f55e1ae3983e4ba https://doi.org/10.1186/s12933-016-0425-2

Topics

Coronary artery disease GLP-1 agonists cardiovascular outcomes

View Full Paper

Ask AI

Bookmark

Implication

Liraglutide does not improve LVEF in T2D with stable CAD; challenges hypothesized systolic benefits and supports neutral effect in this population.

Effects of the glucagon-like peptide-1 receptor agonist liraglutide on systolic function in patients with coronary artery disease and type 2 diabetes: a randomized double-blind placebo-controlled crossover study

Discussion

Member takes

Implication

Structured PICO

Limitations

Cite This Study

Topics

Effects of the glucagon-like peptide-1 receptor agonist liraglutide on systolic function in patients with coronary artery disease and type 2 diabetes: a randomized double-blind placebo-controlled crossover study

Discussion

Member takes

Implication

Structured PICO

Limitations

Cite This Study

Also Consider

Topics

Also Consider